Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm. In patients who’ve been treated with Aduhelm for …

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s …

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS’) restrictive …

Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer’s disease drug Aduhelm has proven more of a headache than a blessing …

Biogen’s Alzheimer’s disease drug Aduhelm has endured a headache of a launch, largely due to lingering questions about its true clinical benefit and how the …

Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a reported death will likely trigger more doubts around its use. One patient …

Even as Biogen dominates biopharma headlines with its high-profile Aduhelm launch, the company’s budding biosimilar business has been quietly building up—and now, it has another …

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer’s disease drug Aduhelm, the company is also feeling the …

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …

Maybe you occasionally forget appointments or social events or lose your train of thought in a conversation. Maybe you’re feeling depressed or overwhelmed when making …